35203-49-7

Usage

Uses

Used in Pharmaceutical Industry:
N1-METHYL-4-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used as a building block for the synthesis of pharmaceuticals due to its ability to be incorporated into complex molecular structures, enhancing the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, N1-METHYL-4-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is utilized as a key intermediate in the production of agrochemicals, contributing to the creation of effective compounds for crop protection and enhancement of agricultural yields.
Used in Organic Synthesis:
N1-METHYL-4-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used as a versatile intermediate in organic synthesis for the preparation of various fine chemicals, taking advantage of its reactivity and structural features to produce a wide array of specialized compounds.
Used in Chemical Research:
As a potential substrate for oxidation reactions, N1-METHYL-4-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is employed in chemical research to explore novel reaction pathways and develop innovative synthetic methods, further expanding the scope of its applications in the chemical sciences.

InChI:InChI=1/C8H9F3N2/c1-13-7-3-2-5(4-6(7)12)8(9,10)11/h2-4,13H,12H2,1H3

Upstream product

• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 400-98-6 4-trifluoromethyl-2-nitroaniline 
• 396-12-3 N-[2-nitro-4-(trifluoromethyl)phenyl]acetamide 
• 300698-92-4 N-methyl-N-[2-nitro-4-(trifluoromethyl)phenyl]acetamide 
• 20200-22-0 α,α,α-Trifluoro-N-methyl-6-nitro-p-toluidine 

Downstream Products

• 690231-92-6 2-chloro-N-(2-methylamino-5-trifluoromethyl-phenyl)-5-nitro-benzamide 
• 53483-66-2 1-methyl-5-(trifluoromethyl)-1H-benzo[d]imidazole 
• 1267635-51-7 C₂₃H₁₇F₃N₂O₂ 
• 37957-76-9 3-dimethylaminomethylene-1-methyl-5-phenyl-7-trifluoromethyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 22365-40-8 triflubazam 
• 1267635-07-3 C₂₁H₂₀F₃N₃O₃ 
• 1224878-13-0 1-methyl-2-(4-nitrophenyl)-5-trifluoromethyl-1H-benzimidazole 
• 1191924-19-2 C₂₂H₁₆Cl₂F₃N₅ 
• 120940-45-6 2,4,6-Trimethyl-benzenesulfonate1-amino-2-(2-ethoxycarbonyl-phenyl)-3-methyl-6-trifluoromethyl-3H-benzoimidazol-1-ium; 
• 120914-48-9 ethyl 2-<1-methyl-5-(trifluoromethyl)benzimidazol-2-yl>benzoate 
• 120914-45-6 2-<1-methyl-5-(trifluoromethyl)benzimidazol-2-yl>benzamide 
• 690231-96-0 2-(2-chloro-5-nitro-phenyl)-1-methyl-5-trifluoromethyl-1H-benzoimidazole 
• 690231-99-3 4-chloro-3-(1-methyl-5-trifluoromethyl-1H-benzoimidazol-2-yl)-phenylamine 
• 120914-47-8 N-(2-Methylamino-5-trifluoromethyl-phenyl)-phthalamic acid 

Relevant academic research and scientific papers

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

C2-Selective Branched Alkylation of Benzimidazoles by Rhodium(I)-Catalyzed C-H Activation

Herein, we report a Rh(I)/bisphosphine/K3PO4 catalytic system allowing for the first time the selective branched C-H alkylation of benzimidazoles with Michael acceptors. Branched alkylation with N,N-dimethyl acrylamide was successfully applied to the alkylation of a broad range of benzimidazoles incorporating a variety of N-substituents and with both electron-rich and -poor functionality displayed at different sites of the arene. Moreover, the introduction of a quaternary carbon was achieved by alkylation with ethyl methacrylate. The method was also shown to be applicable to the C2-selective branched alkylation of azabenzimidazoles.

2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS

The present invention provides compounds that are useful as vaccine adjuvants and/or antitumor agents and methods for producing and using the same. In one particular aspect of the invention, compounds of the invention are of the formula (I) where R1, R2, R3 and Ar1 are those defined herein.

Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly

The discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly is described. Synthesis of analogs of the 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione hit established structure-activity relationships. Replacement of the enamine functionality of the hit series with either an imidazole or a pyrazole ring led to compounds that inhibited both capsid assembly and reverse transcriptase. Optimization of the bicyclic benzodiazepine scaffold to include a 3-phenyl substituent led to lead compound 48, a pure capsid assembly inhibitor with improved antiviral activity.

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

A fused heterocyclic compound of formula (1): wherein, A1 and A2 represent a nitrogen atom or the like, R1, R2, R3 and R4 represent a halogen atom or the like, R2 and R3 represent a halogen atom or the like, R5 represents a C1-C6 chain hydrocarbon group optionally substituted with one or more halogen atoms, or the like, R6 and R7 represent a C1-C4 chain hydrocarbon group substituted with one or more halogen atoms, or the like, and n represents 0 or 1, has an excellent noxious arthropod controlling effect.

Synthesis and antiprotozoal activity of some 2-(trifluoromethyl)-1H- benzimidazole bioisosteres

A series of 2-(trifluoromethyl)-1H-benzimidazole derivatives with various 5- and 6-position bioisosteric substituents (-Cl, -F, -CF3, -CN), namely 1-7, were prepared using a short synthetic route. Each analogue was tested in vitro against the protozoa Giardia intestinalis and Trichomonas vaginalis in comparison with albendazole and metronidazole. Several analogues had IC50 values 1 μM against both species, which make them significantly more potent than either standard. Compound 4 [2,5(6)- bis(trifluoromethyl)-1H-benzimidazole], was 14 times more active than albendazole against T.:vaginalis. This compound (4) also showed moderate antimalarial activity against W2 and D6 strains of Plasmodium falciparum (5.98 and 6.12 μM, respectively). Studying further structure activity relationships through the use of bioisosteric substitution in these benzimidazolic derivatives should provide new leads against protozoal and possibly malarial diseases.

CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to cyclic guanidines, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-β

2-Arylbenzoxazoles, benzothiazoles and benzimidazoles were identified as new classes of potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase-β (LPAAT-β). Effects of selected inhibitors on proliferation of tumor cells in vitro were investigated.

Efficient solution phase synthesis of 2-(N-acyl)-aminobenzimidazoles

An efficient solution phase protocol for the synthesis of 2-(N-acyl)-aminobenzimidazoles is reported. The 2-(N-acyl)-aminobenzimidazole ring system was assembled using SNAr reactions, nitro group reduction, acylthiourea formation and cyclization with EDC. The acyl protected 2-aminobenzimidazole derivatives were obtained in high yield and purity without purification of intermediates or final products. This reaction sequence eliminates the use of highly toxic cyanogen bromide, a reagent commonly used to prepare the 2-aminobenzimidazole ring system.